Skip to main content

Joaquin Castillo Justribo

Institutions of which they are part

Postdoctoral researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Joaquin Castillo Justribo

Institutions of which they are part

Postdoctoral researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Projects

SGR-Cat 2021: Neuroimmunologia Clínica

IP: SGR-Cat 2021: Neuroimmunologia Clínica
Collaborators: Carlos Nos Llopis, SGR-Cat 2021: Neuroimmunologia Clínica, José Ant. Graells Salvador, Jaume Sastre Garriga, Jordi Rio Izquierdo, Ingrid Galán Cartaña, Rosalia Horno Ocaña, Manuel Comabella Lopez, Andrea Serrano Mascarós, Margarida Capell Maymo, SGR-Cat 2021: Neuroimmunologia Clínica, Elisenda Anglada Clofent, Montserrat Aroca Alsina, Sergio Cabello, Carmen Tur Gomez, Gabriel Ig Camiña Rodríguez, Herena Eixarch Ahufinger, Carme Santoyo Medina, Oriol Nualart Mundo, SGR-Cat 2021: Neuroimmunologia Clínica, M Jesus Arevalo Navines, SGR-Cat 2021: Neuroimmunologia Clínica, Augusto Cesar Sao Aviles, SGR-Cat 2021: Neuroimmunologia Clínica, Dunia Muñoz Valdivielso, Carmen Espejo Ruiz, Gaizka Loyola Sanmillan, Mireia Resina Salles, Angela Vidal Jordana, Lucía Gutiérrez Ruiz, Ana Zabalza de Torres, Sergio Vergara Ruiz, Rafael Garcia Merida, Luciana Midaglia Fernandez, Alvaro Cobo Calvo, SGR-Cat 2021: Neuroimmunologia Clínica, Joaquin Castillo Justribo, Milagros Fraga Pereira, Breogan Rodriguez Acevedo, Andres Miguez Gonzalez, Mireia Castillo Juarez, Rucsanda Pinteac, Nicolás Miguel Fissolo
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 40000
Reference: 2021 SGR 00782
Duration: 01/01/2022 - 30/06/2025

Determinación de biomarcadores de lesión neuronal y astrocitaria en suero de paciente con encefalopatía hepática

IP: Macarena Simon-Talero Horga
Collaborators: Joaquin Castillo Justribo, Mònica Pons Delgado
Funding agency: Instituto de Salud Carlos III
Funding: 60500
Reference: PI21/00312
Duration: 01/01/2022 - 30/06/2026

Niveles en suero de neurofilamentos de cadena ligera como marcador pronóstico de evolución de la enfermedad y de respuesta al tratamiento en esclerosis múltiple

IP: Georgina Arrambide García
Collaborators: Jordi Rio Izquierdo, Rosalia Horno Ocaña, Cristina Auger Acosta, Joaquin Castillo Justribo, Mireia Castillo Juarez
Funding agency: Instituto de Salud Carlos III
Funding: 110715
Reference: PI19/01590
Duration: 01/01/2020 - 30/06/2024

TRAtamiento y recuperación VISual en neuritis óptica - Estudio TRAVIS

IP: Jaume Sastre Garriga
Collaborators: Dulce María Moncho Rodríguez, Sergio Cabello, Cristina Auger Acosta, Alex Rovira Cañellas, Ana Zabalza de Torres, Joaquin Castillo Justribo
Funding agency: Instituto de Salud Carlos III
Funding: 96800
Reference: PI19/00950
Duration: 01/01/2020 - 30/06/2024

Related news

A study conducted at the Catalan Multiple Sclerosis Centre (Cemcat) shows that the lack of a reduction in neurofilament light chain during the first year of treatment is associated with a higher risk of subsequent disease activity.

The project’s 4th annual meeting was recently held as part of the Fortalece–Salud programme of the Carlos III Health Institute.

An international study led by researchers from Vall d’Hebron shows that simple tests that patients can perform themselves help detect changes in disability that may occur even in the absence of disease relapses.

Related professionals

Joaquim Vives Armengol

Joaquim Vives Armengol

Main researcher
Musculoskeletal Tissue Engineering
Read more
Leonie Roithmeier

Leonie Roithmeier

Predoctoral researcher
Circadian Rhythms and Ageing Laboratory
Read more
Sílvia Torrents Zapata

Sílvia Torrents Zapata

Research technician
Transfusional Medicine
Read more
Juan Bautista Torralba Paz

Juan Bautista Torralba Paz

Research technician
Maternal and Fetal Medicine
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.